The MidWest Drug Development Conference is now accepting registrations to attend a two-day event focused on highlighting the best early- and mid-stage therapeutic technologies that Midwestern universities have to offer.

The registration page is here.
The conference will be held on Oct. 1-2 in Omaha, Neb., and will feature more than 50 early- and mid-stage technologies that will cover a wide scope of conditions and diseases, including cancer, infectious diseases and central nervous disorders, to name a few. The technologies will be featured in a series of short, 10-minute presentations. Another major feature of the conference will include ample networking opportunities and dedicated spaces where each university can set up one-on-one partnering meetings and showcase other technologies.

Cost is $500 per person, but discount codes will be provided to preferred guests who work in business development at pharmaceutical or other biotech firms. Priority will also be given to venture capitalists and angel investors.

Contact Matt Boehm at to learn how to receive a discount code.

So far the list of participating universities includes Nebraska and the Nebraska Medical Center, Kansas, Kansas State, Iowa, Iowa State, Illinois, Northwestern, Indiana, Purdue, Washington University, and Colorado State.

The event is primarily sponsored and hosted by UNeMed and the University of Nebraska.

Meet new partners, unearth hidden gems at the Midwest Drug Development Conference in Omaha, Nebraska, Oct. 1-2, 2018. A dozen major Midwest medical research institutions with their best and brightest technologies will be in one place, including Colorado State University, Indiana University, Iowa State University, Kansas State University, Northwestern University, Purdue University, University of Illinois-Urbana, University of Iowa, University of Kansas, University of Nebraska, University of Missouri and the University of Washington in St. Louis. Those institutions accounted for (in 2016 according to AUTM data): $5.61 billion in research; 2,119 new inventions; 614 licensing agreements; 581 U.S. patents; 42 new products; 91 startups formed; 10 blockbusters (licensing agreements worth $1 million or more).